| Literature DB >> 16645165 |
Lucia Mazzolai1, Patrick Hohlfeld, Francois Spertini, Daniel Hayoz, Marc Schapira, Michel A Duchosal.
Abstract
Heparin is the drug of choice for the treatment or the prevention of thromboembolic disease during pregnancy. However, treatment options are limited when heparin cannot be used because of hypersensitivity skin reactions. Despite the recent availability of new anticoagulant agents, data relating to their use during pregnancy are lacking. This report describes the successful management with fondaparinux, during 150 days, of a pregnant patient with protein S deficiency and prior deep vein thrombosis (DVT) who developed heparin and danaparoid hypersensitivity.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16645165 DOI: 10.1182/blood-2006-03-009548
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113